The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Topped up! Seen this happening lately with many stocks, Take it down to shake that tree and then go back up. Seems like a go to technique for this MMs
ThePlonker1
Far less brave buying here than buying at AVCT with a market cap of £ 387 Million versus GDR market cap of £ 64 Million
My personal opinion is that the economy needs saliva testing. Nasal swabs and lab turnarounds were great in the spring but the game has moved on. Takes a brave soul to buy into this when the Mcap is £60 million.
This original post of this thread aged well.
Plant power I don't like cross boarding but your behind with your research there.
Fwiw I think the word" could" in the Rns has given the market makers an opportunity .
Star striker needs to score his first goal then your floodgates are open . Gla
I do have a theory that RNS was released due to instructions being uploaded and made publicly available (possibly in error) and shared / highlighted on social media, maybe DB was holding back to year-end update or to allow further progress to be made.
Either way - good progress, just more, much more, to come.
PP
Flush, try DYOR and try June presentation. Just thinking all saliva tests are the same shows you haven't done any research.
@flush
1 bead per reaction, just add sample - the NCYT test requires rehydrating it in bulk and then distributing it to multiple tests. This leads to inaccuracies and inefficiencies compared to the GDR test
Beads are room temperature stable for 12 months - the NCYT test is room temperature stable for shipping only, then needs -20C storage. Reduces the logistics around storage and handling of product. Also allows distribution world wide to every lab without worrying about cold chain.
Internal control built into each test - the NCYT requires separate control standards. This means that the NCYT test has more inconclusive results, the GDR test can tell if the test has not worked due to sample issues
Probe based chemistry - the NCYT test is built around taqman. The GDR test can provide important information on genotype, particularly if there is a mutation in the sequence which would throw the NCYT test and provide a false negative. Genedrive test more robust when it comes to mutations
End point melt - The NCYT test requires realtime machines which are in limited supply. The GDR test can use any standard PCR machine making it cheaper to set up mass testing - important for countries such as India and the US where cost of scale is important
I could go on...
@flushfrank - NYCT swab (nasal / throat)....saliva = spit..holy grail
Exactly BB - predictable :)
Or the RNS that shows validation only part complete, no FDA approval and no sales data hasn’t gone down to well. Hardly a surprise. Lots to come from GDR but not today.
FDA approval and India sales are what I’m banking on so fingers crossed for that.
I don’t get it? Like 6 months behind Novacyt, who is sellling millions, also using saliva.
What is the unique USP?
Traders closing T positions.... investors swoop in picking up cheap shares... rinse & repeat
Tried to sell immediately and quoted 133 then 131. Not great.
Thanks iphone :)
145 1,500 PEEL 07:44
147 1,500 FCAP 07:55
147 2,500 WINS 07:40
147 1,500 SCAP 07:56
155 2,500 JBER 07:55